Description
Retatrutide is an investigational synthetic peptide that acts biochemically as a triple receptor agonist at the GLP-1, GIP, and glucagon receptors, originated by Eli Lilly. It has been evaluated in clinical-trial research and is supplied here solely as a lyophilized research chemical.
Research context: In published laboratory and preclinical research, retatrutide has been studied in the context of incretin (GLP-1, GIP) and glucagon receptor signaling and metabolic-regulation pathways.
Specifications: Molecular mass 4730.91 Da; CAS 2381089-83-2; purity 99.6% (HPLC); 10 mg lyophilized powder in a sealed vial; storage −20°C (24 months).
This product is supplied strictly for in-vitro laboratory research. It is not a drug, food, cosmetic, or dietary supplement, and is not intended for human or animal consumption, medical, veterinary, or household use.
Reviews
There are no reviews yet.